Jennifer Loftis, Ph.D., Principal Investigator
Marilyn Huckans, Ph.D., Co-Core Lead
William Hoffman, Ph.D., M.D., Co-Investigator
Jodi Lapidus, Ph.D., Co-Investigator
The primary objective of the TSC is to standardize the MARC’s procedures for rodent and human genotyping, recruitment and retention, collection of neuropsychiatric data, processing and storage of human blood, and analysis of neurophysiological factors and responses from humans and rodent models.
The TSC will foster existing and develop new partnerships with community-based clinics and addiction treatment centers to optimize recruitment strategies and conduct on- and off-site genotype screening (facilitated by the use of a mobile research unit).
In addition, the TSC will add human specimens (i.e., plasma, peripheral blood mononuclear cells, and oral fluid) to an existing Clinical and Biological Specimen Repository. These de-identified samples will be available for use in future studies to accelerate understanding of MA use disorder, and therefore have significant long-term value to the MARC.